Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly

Blood

Volumn 130, Issue 6, 2017, Pages 742-752

  Zink, Florian ^a   Stacey, Simon N ^a   Norddahl, Gudmundur L ^a   Frigge, Michael L ^a   Magnusson, Olafur T ^a   Jonsdottir, Ingileif ^a,b,c   Thorgeirsson, Thorgeir E ^a   Sigurdsson, Asgeir ^a   Gudjonsson, Sigurjon A ^a   Gudmundsson, Julius ^a   Jonasson, Jon G ^b,d   Tryggvadottir, Laufey ^d   Jonsson, Thorvaldur ^b,c   Helgason, Agnar ^a,e   Gylfason, Arnaldur ^a   Sulem, Patrick ^a   Rafnar, Thorunn ^a   Thorsteinsdottir, Unnur ^a,c   Gudbjartsson, Daniel F ^a,e   Masson, Gisli ^a   Kong, Augustine ^a   Stefansson, Kari ^a,c   more..

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d ICELANDIC CANCER REGISTRY   (Iceland)

^e UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ACSS2 PROTEIN; AKAP17A PROTEIN; ASXL1 PROTEIN; CBL PROTEIN; CEP112 PROTEIN; CREBBP PROTEIN; CUX1 PROTEIN; DNA METHYLTRANSFERASE 3A; GOLGA8B PROTEIN; HRC PROTEIN; JANUS KINASE 2; KMT2D PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NRAS PROTEIN; PPM1D PROTEIN; PROTEIN; PROTEIN P53; ROBO1 PROTEIN; SETDB1 PROTEIN; SF3B1 PROTEIN; SRSF2 PROTEIN; SYNE1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TET2 PROTEIN; UMODL1 PROTEIN; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; ONCOPROTEIN; PPM1D PROTEIN, HUMAN; PROTEIN PHOSPHATASE 2C; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER RISK; CELL LINEAGE; CHROMOSOME LOSS; CLONAL VARIATION; GENEALOGY; GENETIC ASSOCIATION; GENETIC DRIFT; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; ICELANDER; MAJOR CLINICAL STUDY; MORTALITY RATE; MOSAICISM; PHENOTYPE; PRIORITY JOURNAL; SMOKING; SOMATIC MUTATION; TELOMERE LENGTH; WHOLE GENOME SEQUENCING; Y CHROMOSOME; ADULT; AGE; CELL CLONE; CYTOLOGY; FEMALE; GENETICS; HEMATOLOGIC NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MUTATION; RISK FACTOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLONE CELLS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN PHOSPHATASE 2C; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RISK FACTORS;

EID: 85027442392     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-02-769869     Document Type: Article

References (52)

1. Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996; 88(1):59-65.
2. Busque L, Paquette Y, Provost S, et al. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood. 2009;113(15):3472-3474.
3. Fey MF, Liechti-Gallati S, von Rohr A, et al. Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood. 1994;83(4):931-938.
4. Gale RE, Wheadon H, Linch DC. X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol. 1991;79(2):193-197.
5. Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S, Green AR. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol. 1997;97(4):920-926.
6. Sawai CM, Babovic S, Upadhaya S, et al. Hematopoietic stem cells are the major source of multilineage hematopoiesis in adult animals. Immunity. 2016;45(3):597-609.
7. Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108(50):20012-20017.
8. Anger B, Janssen JW, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia. 1990;4(4):258-261.
9. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981; 58(5):916-919.
10. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. 1984;63(6):1318-1323.
11. Wiggans RG, Jacobson RJ, Fialkow PJ, Woolley PV III, Macdonald JS, Schein PS. Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. Blood. 1978;52(4):659-663.
12. Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7(8):941-951.
13. Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111(7):2548-2553.
14. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118.
15. Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122(1):100-108.
16. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488): 328-333.
17. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179-1181.
18. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
19. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
20. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
21. McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports. 2015;10(8): 1239-1245.
22. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12): 1472-1478.
23. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.
24. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
25. Holstege H, Pfeiffer W, Sie D, et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. 2014;24(5): 733-742.
26. Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet. 2015;47(5): 435-444.
27. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9): 1297-1303.
28. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26(16): 2069-2070.
29. Ley TJ, Miller C, Ding L, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22): 2059-2074.
30. Kong A, Masson G, Frigge ML, et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat Genet. 2008;40(9): 1068-1075.
31. Kong A, Steinthorsdottir V, Masson G, et al; DIAGRAM Consortium. Parental origin of sequence variants associated with complex diseases. Nature. 2009;462(7275):868-874.
32. Steinthorsdottir V, Thorleifsson G, Sulem P, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet. 2014;46(3): 294-298.
33. Ding Z, Mangino M, Aviv A, Spector T, Durbin R; UK10K Consortium. Estimating telomere length from whole genome sequence data. Nucleic Acids Res. 2014;42(9):e75.
34. Dingli D, Traulsen A, Michor F. (A)symmetric stem cell replication and cancer. PLOS Comput Biol. 2007;3(3):e53.
35. Akbari MR, Lepage P, Rosen B, et al. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst. 2014; 106(1):djt323.
36. Pharoah PDP, Song H, Dicks E, et al; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. J Natl Cancer Inst. 2016;108(3):djv347.
37. Ruark E, Snape K, Humburg P, et al; Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406-410.
38. Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2016;2(3):370-372.
39. Forsberg LA, Rasi C, Malmqvist N, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46(6):624-628.
40. Jacobs PA, Brunton M, Court Brown WM, Doll R, Goldstein H. Change of human chromosome count distribution with age: evidence for a sex differences. Nature. 1963;197:1080-1081.
41. Pierre RV, Hoagland HC. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer. 1972; 30(4):889-894.
42. Klein AM, Simons BD. Universal patterns of stem cell fate in cycling adult tissues. Development. 2011;138(15):3103-3111.
43. Catlin SN, Busque L, Gale RE, Guttorp P, Abkowitz JL. The replication rate of human hematopoietic stem cells in vivo. Blood. 2011; 117(17):4460-4466.
44. Dingli D, Pacheco JM. Allometric scaling of the active hematopoietic stem cell pool across mammals. PLoS One. 2006;1:e2.
45. Rozhok AI, Salstrom JL, DeGregori J. Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia. Proc Natl Acad Sci USA. 2016;113(4):1050-1055.
46. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371-1374.
47. Gramatges MM, Bertuch AA. Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res. 2013;162(6):353-363.
48. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124(18):2775-2783.
49. Schroeder T. Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior. Cell Stem Cell. 2010;6(3):203-207.
50. Holman CD, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Inst. 1984;72(2):257-266.
51. Werner B, Beier F, Hummel S, et al. Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. eLife. 2015;4:e08687.
52. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA. 2013;110(6): 1999-2004.